- Home
- / Phathom Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Phathom Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$17.4
2024-10-28
Market Capitalization
$1.2 B
2024-10-28
Revenue
$175.1 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 682.0K | 55.3M | 175.1M | |||||
| Cost of goods sold | 167.0K | 8.0M | 22.6M | |||||
| Gross profit | 515.0K | 47.3M | 152.5M | |||||
| Gross profit margin, % | 85.6% | 87.1% | ||||||
| General and administrative expense | 1.2M | 6.9M | 27.5M | 62.7M | 101.0M | 117.9M | 290.7M | 279.7M |
| Operating expense total | 2.5M | 27.3M | 125.7M | 172.4M | 167.8M | 324.7M | 312.5M | |
| EBIT | (1.2M) | (106.2M) | (125.7M) | (135.1M) | (172.4M) | (167.3M) | (277.5M) | (160.0M) |
| EBIT margin, % | -502.2% | -91.4% | ||||||
| Interest income | 1.1M | 1.1M | 41.0K | 2.1M | 7.9M | 15.2M | 7.0M | |
| Interest expense | 13.0K | 4.2M | 42.0M | 17.3M | ||||
| Pre tax profit | (221.2M) | |||||||
| Net Income | (1.3M) | (255.1M) | (129.1M) | (143.9M) | (197.7M) | (201.6M) | (334.3M) | (221.2M) |
| EPS | (5.0) | (3.0) | (5.3) | (3.0) |